Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 25, 2021 07:00 ET | Source: FibroGen, Inc.

FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

SAN FRANCISCO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive topline results from WHITNEY, the Company’s Phase 2 clinical study of roxadustat, a...
August 19, 2021 19:35 ET | Source: FibroGen, Inc.

Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

TOKYO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen")...
August 16, 2021 07:00 ET | Source: FibroGen, Inc.

FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer

SAN FRANCISCO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role. Pat...
August 11, 2021 07:00 ET | Source: FibroGen, Inc.

FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease

SAN FRANCISCO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the...
August 09, 2021 16:01 ET | Source: FibroGen, Inc.

FibroGen Reports Second Quarter 2021 Financial Results

• Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis. • Total roxadustat net sales in China of $52.8 million1 by FibroGen and the distribution entity jointly owned by...
July 29, 2021 07:00 ET | Source: FibroGen, Inc.

FibroGen to Report Second Quarter 2021 Financial Results

SAN FRANCISCO, July 29, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2021 financial results on Monday, August 9 after the market close. FibroGen will also...
July 19, 2021 07:00 ET | Source: FibroGen, Inc

Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform

Exclusive Global Development and Commercialization Rights for Recombinant Human Collagen-Based Biosynthetic Cornea Clinical Stage Asset Has Potential for First Approved Biosynthetic Human Cornea ...
July 15, 2021 18:26 ET | Source: FibroGen, Inc

FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease

SAN FRANCISCO, July 15, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee...
July 12, 2021 07:00 ET | Source: FibroGen, Inc

FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer

SAN FRANCISCO, July 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead...
June 25, 2021 09:15 ET | Source: FibroGen, Inc

Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

TOKYO, June 25, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen")...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right